Evidence map›Paper›PMID 31110348›Full record

ArticleNature medicine2019

IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure.

Lenette L Lu, Malisa T Smith, Krystle K Q Yu, Corinne Luedemann, Todd J Suscovich, Patricia S Grace, Adam Cain, Wen Han Yu, Tanya R McKitrick, Douglas Lauffenburger and 8 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 177 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 2 pooled it
20.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 2 syntheses or guidelines pooled it, 261 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  6. A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Diverse infection models demonstrate robust resistance ofbioRxiv : the preprint server for biology · 2026
    Article
  15. Review
  16. Article
  17. HowVaccines · 2026
    Review
  18. Article
  19. Article
  20. Review

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Lenette L LuDepartment of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA.
Malisa T SmithDepartment of Medicine, University of Washington, Seattle, WA, USA.
Krystle K Q YuDepartment of Medicine, University of Washington, Seattle, WA, USA.
Corinne LuedemannRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Todd J SuscovichRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9811-9792
Patricia S GraceRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Adam CainRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Wen Han YuRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-1671-9744
Tanya R McKitrickDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Douglas LauffenburgerDepartment of Biological Engineering, MIT, Cambridge, MA, USA.
Richard D CummingsDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Harriet Mayanja-KizzaDepartment of Medicine, Makerere University, Kampala, Uganda.ORCID http://orcid.org/0000-0002-9297-6208
Thomas R HawnDepartment of Medicine, University of Washington, Seattle, WA, USA.
W Henry BoomDepartment of Medicine, Case Western Reserve University and Univ. Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Catherine M SteinDepartment of Medicine, Case Western Reserve University and Univ. Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Sarah M FortuneDepartment of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7565-9975
Chetan Seshadri *Department of Medicine, University of Washington, Seattle, WA, USA. seshadri@u.washington.edu.ORCID http://orcid.org/0000-0003-2783-7540
Galit Alter *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. galter@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-7680-9215
Ragon Institute of MGH, MIT and Harvard · USUniversity of Washington · USBeth Israel Deaconess Medical Center · USHarvard University · USUniversity Hospitals of Cleveland · USIIT@MIT · USMakerere University · UG

Funding

INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
Resistance to MTB infection in HIV infected individuals in Uganda and S. AfricaR01AI124348 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY, HAWN, THOMAS R · 2016 to 2020
$11.3M
Overall Priority Score P41GM103694 · NIGMS · EMORY UNIVERSITY · PI CUMMINGS, RICHARD D · 2013 to 2018
$6.9M
Natural Resistance to Mycobacterium Tuberculosis InfectionU01AI115642 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY, MAYANJA-KIZZA, HARRIET · 2015 to 2019
$3.5M
Antibody Mediated Mechanisms of Immune Modulation in TuberculosisK08AI130357 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI LU, LENETTE · 2017 to 2021
$984k
NIAID NIH HHS K08 AI130357NIAID NIH HHS R01 AI124348NIAID NIH HHS T32 AI007061NIAID NIH HHS U01 AI115642NIGMS NIH HHS P41 GM103694
6 · The paper itself

Abstract

Exposure to Mycobacterium tuberculosis (Mtb) results in heterogeneous clinical outcomes including primary progressive tuberculosis and latent Mtb infection (LTBI). Mtb infection is identified using the tuberculin skin test and interferon-γ (IFN-γ) release assay IGRA, and a positive result may prompt chemoprophylaxis to prevent progression to tuberculosis. In the present study, we report on a cohort of Ugandan individuals who were household contacts of patients with TB. These individuals were highly exposed to Mtb but tested negative disease by IFN-γ release assay and tuberculin skin test, 'resisting' development of classic LTBI. We show that 'resisters' possess IgM, class-switched IgG antibody responses and non-IFN-γ T cell responses to the Mtb-specific proteins ESAT6 and CFP10, immunologic evidence of exposure to Mtb. Compared to subjects with classic LTBI, 'resisters' display enhanced antibody avidity and distinct Mtb-specific IgG Fc profiles. These data reveal a distinctive adaptive immune profile among Mtb-exposed subjects, supporting an expanded definition of the host response to Mtb exposure, with implications for public health and the design of clinical trials.

Indexed as

AdultAntibodies, BacterialAntigens, BacterialBiomarkersCD4-Positive T-LymphocytesChildCohort StudiesFemaleHumansInterferon-gammaInterferon-gamma Release TestsLatent TuberculosisMaleMycobacterium tuberculosisTuberculin TestTuberculosisAntibodies, BacterialAntigens, BacterialBiomarkersInterferon-gamma

Identifiers

PMID31110348
PMCPMC6559862
OpenAlexW2946529671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.